ArticleDrug design, development and therapy2025
Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis-Associated Nephritis in Children: A Retrospective Single-Centre Study.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of telitacicept in IgA vasculitis nephritis: a single-center retrospective study.European journal of pediatrics · 2026Article
- Short-term changes in clinical parameters associated with telitacicept in pediatric IgA nephropathy: a single-center self-controlled observational study.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Childhood IgA nephropathy (IgAN) and IgA Vasculitis-associated nephritis (IgAVN) are same in pathogenesis and still a challenge to pediatricians. Purpose: To evaluate the efficacy and safety of Telitacicept in pediatric patients with IgAN or IgAVN. Patients and Methods: This was a retrospective single-centre study of pediatric IgAN or IgAVN with urine protein-to-creatinine ratio (UPCR) over 500 μg/mg who were treated with subcutaneous administration of Telitacicept and followed for at least 6 months. The effects on induction of remission and side effects were evaluated. Results: 13 pediatric patients including 7 with IgAN and 6 with IgAVN were enrolled in the study. After 6-month treatment, 6 of 13 (46.15%) patients achieved remission, 4 (30.77%) patient achieved complete remission. The median percent reduction in UPCR was 90.74% (84.38%, 94.76%). The median percent reduction in urine red blood cells count was 96.21% (75.33%, 98.99%). Compared with baseline, serum albumin increased significantly [ Conclusion: Telitacicept was safe in pediatric IgAN/IgAVN patients and could significantly induce renal remission through reducing proteinuria and hematuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.